Kedokteran & Kesehatan editorial
Open AccessOA2022
Phase II clinical trial of neoadjuvant and adjuvant pembrolizumab in resectable local-regionally advanced head and neck squamous cell carcinoma
In a phase II trial of 92 patients with resectable locally advanced HNSCC, neoadjuvant and adjuvant pembrolizumab yielded 1-year DFS of 97% in intermediate-risk and 66% in high-risk patients. Pathological response to neoadjuvant PD-1 blockade correlated with improved DFS.
T. Wise-Draper; S. Gulati; Sarah Palackdharry; B. Hinrichs; F. Worden; M. Old; N. Dunlap; J. Kaczmar; Yash J. Patil; M. K. Riaz; Alice L. Tang; J. Mark; C. Zender; A. Gillenwater; D. Bell; N. Kurtzweil; Maria Mathews; C. Allen; M. Mierzwa; K. Casper; R. Jandarov; M. Medvedovic; J. J. Lee; Nusrat Harun; V. Takiar; M. Gillisonยท Clinical Cancer Researchยท 2022ยท DOI 10.1158/1078-0432.CCR-21-3351
The core problem
Patients with resected, locally advanced head and neck squamous cell carcinoma (HNSCC) face a 1-year disease-free survival (DFS) of only 65โ69% despite adjuvant (chemo)radiotherapy. Neoadjuvant PD-1 immune checkpoint blockade (ICB) has shown clinical activity, but biomarkers of response and its impact on survival remain unclear. This phase II trial evaluated neoadjuvant and adjuvant pembrolizumab in resectable HNSCC, stratified by risk factors, to assess 1-year DFS, overall survival (OS), pathological response (PR), and safety.
Innovation
Eligible patients had resectable squamous cell carcinoma of the oral cavity, larynx, hypopharynx, or oropharynx (p16-negative) with clinical stage T3-T4 and/or โฅ2 nodal metastases or clinical extracapsular nodal extension (ENE). Patients received neoadjuvant pembrolizumab 200 mg 1โ3 weeks before surgery. After surgery, they were stratified by absence (intermediate-risk) or presence (high-risk) of positive margins and/or ENE. All patients received adjuvant radiotherapy (60โ66 Gy) with concurrent pembrolizumab every 3 weeks for 6 doses. High-risk patients also received weekly cisplatin (40 mg/mยฒ). The primary endpoint was 1-year DFS; secondary endpoints were 1-year OS and pathological response (PR). Safety was assessed per CTCAE v5.0.
Introduction
Patients with resected, locally advanced head and neck squamous cell carcinoma (HNSCC) face a 1-year disease-free survival (DFS) of only 65โ69% despite adjuvant (chemo)radiotherapy. Neoadjuvant PD-1 immune checkpoint blockade (ICB) has shown clinical activity, but biomarkers of response and its impact on survival remain unclear. This phase II trial evaluated neoadjuvant and adjuvant pembrolizumab in resectable HNSCC, stratified by risk factors, to assess 1-year DFS, overall survival (OS), pathological response (PR), and safety.
Why it matters
Neoadjuvant and adjuvant pembrolizumab improved 1-year DFS in intermediate-risk HNSCC relative to historical controls, but not in high-risk patients. Pathological response to neoadjuvant ICB emerged as a promising surrogate for DFS, suggesting that treatment adaptation based on PR could be explored in future trials. The lack of benefit in high-risk patients may warrant alternative strategies, such as intensification of adjuvant therapy or incorporation of additional immune-modulating agents. The safety profile was consistent with known pembrolizumab toxicities.
Who should read this
Pembaca Research Digest dan praktisi rumpun ini.
Opening member contentโฆ